Which CLL patients would benefit from intensive therapy?
Treating CLL with venetoclax
New endpoints in clinical trials to better serve patients
Elihu H. Estey
Advances in low grade lymphoma over the past 40 years
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL